Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of cetuximab + avelumab plus doublet chemotherapy in non-small cell lung cancer
2018-001529-24Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and avelumab in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Primary endpoint: Confirmed best overall response rate. Started Jul 2018; status: completed.
02
Drugs
cetuximabavelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001529-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001529-24.